Key Stats for Johnson and Johnson Stock
- Price change for Johnson and Johnson stock in the last 12 months: 59%
- $JNJ Stock Price as of Jul. 28: $267
- 52-Week High: $275
- $JNJ Stock Price Target: $271
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Johnson and Johnson (JNJ) stock is in focus today after the company announced a $5.5 billion agreement to resolve its remaining talc litigation. The deal is conditioned on at least 95% of remaining claimants agreeing to participate, and it would wrap up roughly 76,000 pending ovarian talc cases.
The settlement follows a favorable court ruling. On July 22, 2026, a federal court overseeing the multi-district litigation ordered plaintiffs to explain why their remaining claims shouldn’t be dismissed, since they couldn’t prove the company’s talc products caused any specific person’s ovarian cancer.
That ruling came after plaintiffs withdrew their expert witnesses on causation in two test cases, following a hearing that found their opinions weren’t based on reliable science.
Johnson & Johnson’s Worldwide VP of Litigation, Erik Haas, said the company believes it would have continued winning cases if litigation had continued, since it has already prevailed in most ovarian cases tried so far.
But the settlement allows the company to move past the issue and focus on its core business.
Under the terms, the first payment of up to $3 billion is due in 2027, with no further payments required before 2028.
This builds on earlier progress, since the company already settled about 95% of filed mesothelioma lawsuits, all state consumer protection claims, and all talc-supplier disputes.
Johnson and Johnson has maintained that decades of independent research show talc is safe and doesn’t cause cancer.
This settlement news arrives alongside a strong Q2 for Johnson and Johnson stock.
- Revenue reached $25.3 billion, up 5.6% operationally,
- The company raised its full-year guidance to $100.6 billion at the midpoint.
- Adjusted earnings per share guidance moved up to a range of $11.50 to $11.65.
- Innovative Medicine sales grew 6.8% to $16.4 billion, led by DARZALEX at $4 billion and TREMFYA growing 71%.
- MedTech sales rose 3.6% to $8.9 billion, with some softness in cardiovascular offset by strength in vision and orthopedics.
See analysts’ growth forecasts and price targets for Johnson and Johnson stock (It’s free) >>>
What the Market Is Telling Us About Johnson and Johnson Stock
Resolving a 15-year legal overhang removes a major source of uncertainty for investors in Johnson & Johnson stock.
Litigation costs and unpredictable jury verdicts have weighed on sentiment for years, so a defined settlement amount with a clear payment schedule gives investors something concrete to model rather than an open-ended risk.
The timing also matters.
With Johnson and Johnson stock already benefiting from raised guidance and strong new product launches like ICOTYDE and INLEXZO, closing out the talc litigation lets management and investors focus on the company’s underlying growth story heading into 2027 and beyond.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Johnson and Johnson Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
